322 related articles for article (PubMed ID: 33687951)
21. CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.
He X; Kong X; Yan J; Yan J; Zhang Y; Wu Q; Chang Y; Shang H; Dou Q; Song Y; Liu F
Tumour Biol; 2015 Mar; 36(3):1437-44. PubMed ID: 25663456
[TBL] [Abstract][Full Text] [Related]
22. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
23. [The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells].
Kremenetskaia OS; Logacheva NP; Baryshnikov AIu; Chumakov PM; Kopnin BP
Tsitologiia; 1996; 38(12):1280-93. PubMed ID: 9163103
[TBL] [Abstract][Full Text] [Related]
24. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.
Bajgelman MC; Strauss BE
Prostate; 2006 Sep; 66(13):1455-62. PubMed ID: 16741917
[TBL] [Abstract][Full Text] [Related]
25. Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells.
Kremenetskaya OS; Logacheva NP; Baryshnikov AY; Chumakov PM; Kopnin BP
Oncol Res; 1997; 9(4):155-66. PubMed ID: 9268986
[TBL] [Abstract][Full Text] [Related]
26.
Shirole NH; Pal D; Kastenhuber ER; Senturk S; Boroda J; Pisterzi P; Miller M; Munoz G; Anderluh M; Ladanyi M; Lowe SW; Sordella R
Elife; 2016 Oct; 5():. PubMed ID: 27759562
[No Abstract] [Full Text] [Related]
27. Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.
Okal A; Matissek KJ; Matissek SJ; Price R; Salama ME; Janát-Amsbury MM; Lim CS
Gene Ther; 2014 Oct; 21(10):903-12. PubMed ID: 25077773
[TBL] [Abstract][Full Text] [Related]
28. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.
Perez RE; Knights CD; Sahu G; Catania J; Kolukula VK; Stoler D; Graessmann A; Ogryzko V; Pishvaian M; Albanese C; Avantaggiati ML
J Cell Physiol; 2010 Nov; 225(2):394-405. PubMed ID: 20589832
[TBL] [Abstract][Full Text] [Related]
29. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
Amelio I; Mancini M; Petrova V; Cairns RA; Vikhreva P; Nicolai S; Marini A; Antonov AA; Le Quesne J; Baena Acevedo JD; Dudek K; Sozzi G; Pastorino U; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10869-E10878. PubMed ID: 30381462
[TBL] [Abstract][Full Text] [Related]
30. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.
Müller P; Ceskova P; Vojtesek B
J Biol Chem; 2005 Feb; 280(8):6682-91. PubMed ID: 15613472
[TBL] [Abstract][Full Text] [Related]
31. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
[TBL] [Abstract][Full Text] [Related]
32. Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.
Calhoun S; Daggett V
Biochemistry; 2011 Jun; 50(23):5345-53. PubMed ID: 21561095
[TBL] [Abstract][Full Text] [Related]
33. Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer.
Villiard E; Brinkmann H; Moiseeva O; Mallette FA; Ferbeyre G; Roy S
BMC Evol Biol; 2007 Sep; 7():180. PubMed ID: 17903248
[TBL] [Abstract][Full Text] [Related]
34. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
35. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
[TBL] [Abstract][Full Text] [Related]
36. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
[TBL] [Abstract][Full Text] [Related]
37. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.
Joerger AC; Allen MD; Fersht AR
J Biol Chem; 2004 Jan; 279(2):1291-6. PubMed ID: 14534297
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
39. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.
Gogna R; Madan E; Kuppusamy P; Pati U
J Biol Chem; 2012 Jan; 287(4):2907-14. PubMed ID: 22147694
[TBL] [Abstract][Full Text] [Related]
40. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.
Chen S; Wu JL; Liang Y; Tang YG; Song HX; Wu LL; Xing YF; Yan N; Li YT; Wang ZY; Xiao SJ; Lu X; Chen SJ; Lu M
Cancer Cell; 2021 Feb; 39(2):225-239.e8. PubMed ID: 33357454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]